Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POPLAR-NF2: REC-2282 in Progressive NF2 Mutated Meningiomas
NCT05130866Phase 3Terminated
- Sponsor
- Recursion Pharmaceuticals
- Start
- Jun 2022
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of AR-42 in neurofibromatosis type 2 (NF2), meningioma, sponsored by Recursion Pharmaceuticals. Started Jun 2022; status: terminated.
02
Drugs
AR-42
03
Conditions
neurofibromatosis type 2 (NF2)meningioma
Beyond the preview
Go deeper on NCT05130866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05130866.